Cargando…

Cysteine-to-lysine transfer antibody fragment conjugation

The modification of lysine residues with acylating agents has represented a ubiquitous approach to the construction of antibody conjugates, with the resulting amide bonds being robustly stable and clinically validated. However, the conjugates are highly heterogeneous, due to the presence of numerous...

Descripción completa

Detalles Bibliográficos
Autores principales: Forte, Nafsika, Benni, Irene, Karu, Kersti, Chudasama, Vijay, Baker, James R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Royal Society of Chemistry 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066670/
https://www.ncbi.nlm.nih.gov/pubmed/32190247
http://dx.doi.org/10.1039/c9sc03825f
_version_ 1783505289294643200
author Forte, Nafsika
Benni, Irene
Karu, Kersti
Chudasama, Vijay
Baker, James R.
author_facet Forte, Nafsika
Benni, Irene
Karu, Kersti
Chudasama, Vijay
Baker, James R.
author_sort Forte, Nafsika
collection PubMed
description The modification of lysine residues with acylating agents has represented a ubiquitous approach to the construction of antibody conjugates, with the resulting amide bonds being robustly stable and clinically validated. However, the conjugates are highly heterogeneous, due to the presence of numerous lysines on the surface of the protein, and greater control of the sites of conjugation are keenly sought. Here we present a novel approach to achieve the targeted modification of lysines distal to an antibody fragment's binding site, using a disulfide bond as a temporary ‘hook’ to deliver the acylating agent. This cysteine-to-lysine transfer (CLT) methodology offers greatly improved homogeneity of lysine conjugates, whilst retaining the advantages offered by the formation of amide linkages.
format Online
Article
Text
id pubmed-7066670
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-70666702020-03-18 Cysteine-to-lysine transfer antibody fragment conjugation Forte, Nafsika Benni, Irene Karu, Kersti Chudasama, Vijay Baker, James R. Chem Sci Chemistry The modification of lysine residues with acylating agents has represented a ubiquitous approach to the construction of antibody conjugates, with the resulting amide bonds being robustly stable and clinically validated. However, the conjugates are highly heterogeneous, due to the presence of numerous lysines on the surface of the protein, and greater control of the sites of conjugation are keenly sought. Here we present a novel approach to achieve the targeted modification of lysines distal to an antibody fragment's binding site, using a disulfide bond as a temporary ‘hook’ to deliver the acylating agent. This cysteine-to-lysine transfer (CLT) methodology offers greatly improved homogeneity of lysine conjugates, whilst retaining the advantages offered by the formation of amide linkages. Royal Society of Chemistry 2019-10-11 /pmc/articles/PMC7066670/ /pubmed/32190247 http://dx.doi.org/10.1039/c9sc03825f Text en This journal is © The Royal Society of Chemistry 2019 http://creativecommons.org/licenses/by/3.0/ This article is freely available. This article is licensed under a Creative Commons Attribution 3.0 Unported Licence (CC BY 3.0)
spellingShingle Chemistry
Forte, Nafsika
Benni, Irene
Karu, Kersti
Chudasama, Vijay
Baker, James R.
Cysteine-to-lysine transfer antibody fragment conjugation
title Cysteine-to-lysine transfer antibody fragment conjugation
title_full Cysteine-to-lysine transfer antibody fragment conjugation
title_fullStr Cysteine-to-lysine transfer antibody fragment conjugation
title_full_unstemmed Cysteine-to-lysine transfer antibody fragment conjugation
title_short Cysteine-to-lysine transfer antibody fragment conjugation
title_sort cysteine-to-lysine transfer antibody fragment conjugation
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066670/
https://www.ncbi.nlm.nih.gov/pubmed/32190247
http://dx.doi.org/10.1039/c9sc03825f
work_keys_str_mv AT fortenafsika cysteinetolysinetransferantibodyfragmentconjugation
AT benniirene cysteinetolysinetransferantibodyfragmentconjugation
AT karukersti cysteinetolysinetransferantibodyfragmentconjugation
AT chudasamavijay cysteinetolysinetransferantibodyfragmentconjugation
AT bakerjamesr cysteinetolysinetransferantibodyfragmentconjugation